Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Dose-Ranging Study to Assess the Efficacy, Safety, Tolerability, and Pharmacokinetics of BIIB033 in Subjects With Relapsing Forms of Multiple Sclerosis When Used Concurrently With Avonex

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Dec 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Opicinumab (Primary) ; Interferon beta-1a
  • Indications Multiple sclerosis
  • Focus Proof of concept; Therapeutic Use
  • Acronyms SYNERGY
  • Sponsors Biogen

    • Most Recent Events

    • 12 Oct 2018 Results assessing biomarkers of remyelination and patient stratification for opicinumab treatment effect, presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
    • 28 Oct 2017 Results of a post-hoc analysis studying demographic and baseline predictors of opicinumab treatment response, and identifying a subpopulation with a greater treatment response presented at the 7th Joint Congress of the European Committee for Treatment and Research in Multiple Sclerosis and Americas Committee for Treatment and Research in Multiple Sclerosis
    • 18 Oct 2017 Data from this trial will be presented at the ECTRIMS-ACTRIMS 2017 meeting, according to a Biogen media release.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top